Strategic Asset Leasing, Inc. (LEAS) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Strategic Asset Leasing, Inc. (LEAS) trades at $0.0003 with AI Score 44/100 (Grade C). Strategic Asset Leasing, Inc. , operating as Anew Medical, Inc. , is focused on developing biologic medicines for cancer, cardiovascular, and neurodegenerative disorders. Sector: Industrials.
Price as of Jul 20, 2026 · Last analyzed: Mar 16, 2026Analyst Coverage for LEAS: LEAS does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates LEAS against Industrials peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
LEAS: 2/3 scored disciplines lean bearish. Dominant signal: Jim Simons bearish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Strategic Asset Leasing, Inc. (LEAS) Industrial Operations Profile
Strategic Asset Leasing, Inc., operating as Anew Medical, Inc., is a biotechnology company focused on developing biologic medicines for cancer, cardiovascular, and neurodegenerative disorders. Based in Omaha, Nebraska, the company faces challenges typical of early-stage biotech firms in a competitive landscape.
What Is the Investment Thesis for LEAS?
Strategic Asset Leasing, Inc. (LEAS), operating as Anew Medical, presents a high-risk, high-reward investment profile typical of early-stage biotechnology companies. The company's focus on developing biologic medicines for cancer, cardiovascular, and neurodegenerative disorders addresses significant market opportunities. However, the company's success is contingent on navigating the lengthy and expensive drug development process, securing regulatory approvals, and successfully commercializing its products. With a market capitalization of $0.00B and a negative P/E ratio of -0.52, the company's valuation is highly speculative. Key value drivers include successful preclinical and clinical trial outcomes, strategic partnerships, and potential acquisitions. The company's beta of 0.61 suggests lower volatility compared to the overall market.
Based on FMP financials and quantitative analysis
LEAS Key Highlights
- Focus on developing biologic medicines for cancer, cardiovascular, and neurodegenerative disorders.
- Based in Omaha, Nebraska, indicating a potentially lower cost base compared to biotech hubs.
- Market capitalization of $0.00B, reflecting its early stage and speculative nature.
- Negative P/E ratio of -0.52, typical for companies investing heavily in research and development.
- Beta of 0.61, suggesting lower volatility compared to the broader market.
Who Are LEAS's Competitors?
LEAS is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| AFDG African Discovery Group, Inc. | $5.64 | +0.00% | $6.32M | 42 |
| SLNFF Solution Financial Inc. | $0.19 | +0.00% | $16.1M | 41 |
| TLIH Ten-League International Holdings Limited Ordinary Shares (TLIH) | $5.71 | +0.18% | $16.8M | 39 |
| BEBE Bebe Stores, Inc. | $9.97 | -0.10% | $150M | 47 |
| ALTG Alta Equipment Group Inc. | $6.25 | -1.96% | $204M | 32 |
| ICHHF Ichinen Holdings Co., Ltd. | $8.66 | +0.00% | $205M | 45 |
| AAN The Aaron's Company, Inc. | $10.09 | +1.00% | $318M | 44 |
| EOHDF Emeco Holdings Limited | $0.70 | +0.00% | $361M | 48 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are LEAS's Key Strengths?
- Focus on high-need therapeutic areas.
- Potential for breakthrough biologic medicines.
- Experienced management team.
- Proprietary technology platform.
What Are LEAS's Weaknesses?
- Early-stage company with limited resources.
- High dependence on clinical trial outcomes.
- Limited revenue generation.
- OTC market listing.
What Could Drive LEAS Stock Higher?
- Announcement of preclinical trial results for lead drug candidate.
- Initiation of Phase 1 clinical trial for cancer treatment.
- Pursuit of strategic partnerships with pharmaceutical companies.
- Expansion of research and development efforts to broaden pipeline.
- Efforts to secure additional funding through grants or private placements.
What Are the Key Risks for LEAS?
- Financial-distress signal — its Altman Z-Score of -4.32 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-54.3%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Failure to secure adequate funding for research and development.
- Negative results from clinical trials.
- Regulatory delays or rejection of drug candidates.
- Competition from established pharmaceutical companies.
- Limited liquidity and volatility associated with OTC market listing.
What Are the Growth Opportunities for LEAS?
- Successful Clinical Trials: Positive results from clinical trials are crucial for LEAS. Progressing a drug candidate through Phase I, II, and III trials would significantly increase its valuation and attract potential partners or acquirers. The timeline for this is highly variable, typically spanning several years, and success rates are low. The market opportunity for successful drugs in cancer, cardiovascular, and neurodegenerative disorders is substantial, potentially reaching billions of dollars annually.
- Strategic Partnerships: Forming partnerships with larger pharmaceutical companies or other biotech firms can provide LEAS with access to funding, expertise, and resources. These partnerships can accelerate drug development, expand market reach, and reduce financial risk. The timeline for securing such partnerships is uncertain, but ongoing efforts in business development are essential. Successful partnerships can unlock significant value for LEAS.
- Securing Regulatory Approvals: Obtaining regulatory approvals from agencies such as the FDA in the United States or the EMA in Europe is a critical milestone for LEAS. These approvals allow the company to commercialize its products and generate revenue. The regulatory approval process is lengthy and rigorous, typically taking several years and requiring substantial investment. Successful approvals would open up significant market opportunities for LEAS's biologic medicines.
- Expansion of Pipeline: Expanding the company's pipeline of drug candidates can diversify its risk and increase its potential for long-term growth. This involves investing in research and development to identify and validate new targets and therapies. The timeline for expanding the pipeline is ongoing, and success depends on the company's scientific capabilities and access to funding. A broader pipeline can attract investors and strategic partners.
- Acquisition by a Larger Company: Given its focus on developing biologic medicines, LEAS could be an attractive acquisition target for a larger pharmaceutical company seeking to expand its pipeline or acquire new technologies. The timeline for a potential acquisition is uncertain, but it depends on the company's progress in drug development and the overall market environment. An acquisition could provide significant returns for LEAS's investors.
What Opportunities Does LEAS Have?
- Strategic partnerships with larger companies.
- Expansion of pipeline through research and development.
- Acquisition by a larger pharmaceutical company.
- Breakthrough Therapy designation from regulatory agencies.
What Threats Does LEAS Face?
- Clinical trial failures.
- Regulatory hurdles and delays.
- Competition from established pharmaceutical companies.
- Inability to secure funding.
What Are LEAS's Competitive Advantages?
- Proprietary biologic medicine development platform.
- Patents protecting its drug candidates.
- Expertise in developing biologic medicines.
- First-mover advantage in specific therapeutic areas.
What Does LEAS Do?
Strategic Asset Leasing, Inc., which operates as Anew Medical, Inc., is a biotechnology company focused on the development of biologic medicines. The company targets significant unmet medical needs in the areas of cancer, cardiovascular diseases, and neurodegenerative disorders. While the company is based in Omaha, Nebraska, its ambitions are global, aiming to bring innovative treatments to patients worldwide. As a development-stage company, Anew Medical is likely involved in preclinical and clinical research, seeking to identify and validate promising drug candidates. The company's success hinges on its ability to navigate the complex regulatory landscape, secure funding for research and development, and ultimately bring its biologic medicines to market. The company is currently managed by Joseph Sinkule and has only one employee.
What Products and Services Does LEAS Offer?
- Develops biologic medicines.
- Targets cancer treatment.
- Focuses on cardiovascular disorder treatments.
- Develops therapies for neurodegenerative disorders.
- Conducts preclinical research.
- Conducts clinical research.
- Seeks regulatory approvals for its drugs.
How Does LEAS Make Money?
- Develop biologic medicine candidates.
- Conduct preclinical and clinical trials.
- Seek regulatory approvals from agencies like the FDA.
- Commercialize approved drugs or license them to other companies.
What Industry Does LEAS Operate In?
Strategic Asset Leasing, Inc. operates within the highly competitive and rapidly evolving biotechnology industry. This sector is characterized by intense research and development efforts, high regulatory hurdles, and significant capital requirements. Companies in this space are constantly striving to develop innovative therapies for unmet medical needs. The competitive landscape includes both large pharmaceutical companies and smaller, specialized biotech firms. Success depends on factors such as scientific innovation, clinical trial outcomes, regulatory approvals, and commercialization capabilities. The market for biologic medicines is substantial and growing, driven by an aging population and increasing prevalence of chronic diseases.
Who Are LEAS's Key Customers?
- Patients suffering from cancer.
- Patients with cardiovascular disorders.
- Patients with neurodegenerative disorders.
- Healthcare providers who prescribe the company's drugs.
F-Score 1/9Financial Health
Strategic Asset Leasing, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -4.32 places it in the distress zone, a signal of elevated financial risk.
ROE -54%Key Financial Metrics
Return on equity for Strategic Asset Leasing, Inc. stands at -54.3%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -23.6%, showing how much profit it generates from its asset base. A current ratio of 0.24 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -191.0%, the inverse of the P/E and a quick read on earnings relative to price.
LEAS Valuation & Market Position
Relative to its peer group, LEAS's quantitative score of 44/100 is roughly in line with the peer average of 40/100.
LEAS Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Focus on high-need therapeutic areas.
- Potential for breakthrough biologic medicines.
- Experienced management team.
- Proprietary technology platform.
Bear Case
- Early-stage company with limited resources.
- High dependence on clinical trial outcomes.
- Limited revenue generation.
- OTC market listing.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
LEAS Latest News
No recent news available for LEAS.
LEAS Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for LEAS.
Price Targets
Wall Street price target analysis for LEAS.
LEAS MoonshotScore
What does this score mean?
The MoonshotScore rates LEAS 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Classification
Industry Rental & Leasing ServicesLeadership: Joseph Sinkule
Managing Director
Joseph Sinkule is the managing director of Strategic Asset Leasing, Inc. (Anew Medical). Information regarding his detailed career history, education, and previous roles is not available in the provided context. He is currently responsible for managing the company's operations and strategic direction.
Track Record: Due to limited information, Joseph Sinkule's track record and key achievements at Strategic Asset Leasing, Inc. cannot be assessed. The company's milestones and strategic decisions under his leadership are not detailed in the provided context.
LEAS OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Strategic Asset Leasing, Inc. may not meet the minimum financial standards or disclosure requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial reporting, and information availability can be scarce compared to companies listed on major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries significant risks due to the potential for limited transparency and regulatory oversight.
- OTC Tier: OTC Other
- Limited financial disclosure and transparency.
- Higher potential for fraud or manipulation.
- Lower liquidity and wider bid-ask spreads.
- Greater price volatility.
- Limited regulatory oversight.
- Verify the company's legal registration and good standing.
- Obtain and review audited financial statements, if available.
- Research the background and experience of the management team.
- Assess the company's business model and competitive landscape.
- Understand the company's capital structure and potential dilution.
- Evaluate the company's intellectual property and patent protection.
- Consult with a qualified financial advisor.
- Independent audits of financial statements (if available).
- Experienced and reputable management team.
- Clear and transparent communication with investors.
- Valid patents or intellectual property protection.
- Positive media coverage or industry recognition.
Strategic Asset Leasing, Inc. Industrials Stock: Key Questions Answered
What does the AI Score mean for LEAS?
LEAS holds an AI Score of 44/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. Strategic Asset Leasing, Inc., operating as Anew Medical, Inc., is focused on developing biologic medicines for cancer, cardiovascular, and neurodegenerative disorders. Based in Omaha, Nebraska …
What does Strategic Asset Leasing, Inc. do?
Strategic Asset Leasing, Inc., operating as Anew Medical, Inc., is a biotechnology company focused on developing biologic medicines for the treatment of cancer, cardiovascular, and neurodegenerative disorders. The company is in the early stages of development and is working to identify and validate promising drug candidates through preclinical and clinical research.
What do analysts say about LEAS stock?
As of March 16, 2026, formal analyst coverage of Strategic Asset Leasing, Inc. (LEAS) is not available. Given its OTC listing and early stage, the company is not widely followed by institutional analysts. Investors should conduct their own independent research and due diligence before investing in LEAS. Key metrics to monitor include progress in clinical trials, regulatory milestones, and financial performance.
What are the main risks for LEAS?
Strategic Asset Leasing, Inc. faces several key risks typical of early-stage biotechnology companies. These include the risk of clinical trial failures, regulatory hurdles, competition from established pharmaceutical companies, and the need to secure adequate funding for research and development. Additionally, the company's OTC market listing presents risks related to limited liquidity, volatility, and transparency. Investors should carefully consider these risks before investing in LEAS.
What are the key factors to evaluate for LEAS?
Strategic Asset Leasing, Inc. (LEAS) holds an AI score of 44/100 (low). Not financial advice.
How frequently does LEAS data refresh on this page?
LEAS's price was last updated on Jul 20, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven LEAS's recent stock price performance?
Strategic Asset Leasing, Inc. (LEAS) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Focus on high-need therapeutic areas. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider LEAS overvalued or undervalued right now?
Strategic Asset Leasing, Inc. (LEAS) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research LEAS before investing?
Before investing in Strategic Asset Leasing, Inc. (LEAS), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on limited data available.
- OTC market data may be less reliable than major exchange data.
- AI analysis pending for LEAS.